Firstly, it indicates that MYC overexpression is associated with poor DFS/RFS and OS, that demonstrates that MYC may be a potential therapeutic target of breast cancer, especially in phenotype of negative hormone receptors. This evidence concerns the gene NR4A1 and breast carcinoma.